A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
Year: 2010
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: A. M. Traynor, R. Kurzrock, H. H. Bailey, S. Attia, C. Scheffold, B. van Leeuwen, B. Wu, G. S. Falchook, S. L. Moulder, J. Wheler
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2521990857